Navigation Links
DNA with a twist: New company to search for cancer drugs and antibiotics
Date:2/13/2008

A new company has joined the fight against MRSA and cancer. Researchers at the John Innes Centre (Norwich) have launched a new company, Inspiralis Ltd, based around their expertise in DNA topoisomerases a group of enzymes that help DNA molecules to unravel and wind up properly and not to become tangled during replication.

DNA becomes tangled as a result of various cellular processes, such as replication, which ultimately stops these processes continuing. DNA topoisomerases untangle it. Without them cells die, says Inspiralis co-founder Dr Nicolas Burton.

Topoisomerases are already targets for several drugs, including anti-tumour drugs and antibiotics, such as ciprofloxacin the anti-anthrax drug. The search is now on for new ways of inhibiting them. Inspiralis Ltd make a range of products targeted to the pharmaceutical industry to enable drug-discovery work in this area including topoisomerase enzymes themselves as well as associated products.

A new high-throughput assay, developed recently in the laboratory of Prof. Tony Maxwell of the John Innes Centre (and co-founder of Inspiralis), will also provide a huge advance on the standard gel-based screening method for topoisomerase inhibitors. Inspiralis Ltd will develop the technique further as well as offering screening services to companies. The assay will potentially allow millions of compounds to be screened for activity rather than just hundreds, says Dr Burton.

The technology can now be accessed as a service or as a kit helping pharmaceutical companies and academics to screen for new and better cancer drugs and antibiotics.

Some powerful antibiotics and key anti-cancer drugs act by inhibiting topoisomerases. In cancer, cells rapidly divide in an uncontrolled manner and topoisomerase inhibitors can block this uncontrolled cell division.

Topoisomerase inhibitors are key targets for new drug development, says Mrs Alison Howells (co-founde
'/>"/>

Contact: Zoe Dunford
zoe.dunford@bbsrc.ac.uk
44-016-032-55111
Norwich BioScience Institutes
Source:Eurekalert  

Page: 1 2

Related medicine news :

1. Owner and Operator of Florida Durable Medical Equipment Company Convicted of Medicare Fraud
2. Claim Filed Against the Company and Nine Other Defendants in the Haifa Magistrates Court
3. Cleveland-based Health Care Tech Company Within3 Names New CEO
4. Elliott Extremely Dissatisfied With Genzyme Bid for Bioenvision; Believes Offer Significantly Undervalues Company
5. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
6. Neusoft Becomes First Global Growth Company Partner of World Economic Forum
7. Statement of Eli Lilly and Company on Dr. David Egilman Settlement:
8. Exponent to Present at the Upcoming Sidoti & Company Investor Forum and William Blair Small-Cap Growth Stock Conference
9. Perrigo Company to Host Analyst Meeting on September 18, 2007
10. The NeoStrata Company Appoints a New Vice President of Operations
11. Akers Biosciences, Inc. ABI or the Company Receipt of Further United States Military Contracts

Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
DNA with a twist: New company to search for cancer drugs and antibiotics
DNA with a twist: New company to search for cancer drugs and antibiotics
(Date:11/27/2009)...all/--TheGymboreeCorporation(Nasdaq: GYMB )announc...MX23rdInvestorProgram,whichwillbeheldattheMayFairH...11:45a.m.GMT. ,, TolistentoalivebroadcastofTheG...easelogontowww.gymboree.com,clickon"OurCompany"att...ndthen"ConferenceCalls&Webcasts."Thewebcastwil...
(Date:11/27/2009)...e-FirstCall/--ShamirOpticalIndustryLtd.(Nasdaq: SH...ctsandtechnologytotheophthalmiclensmarket,announce...istributioninanaggregateamountofUS$10million(appro...presentativerateofexchange),orapproximatelyUS$0.60...esentativerateofexchange)perordinarysharebasedonth...
(Date:11/27/2009)... economic burdens, study predicts , , FR...ople with diabetes in the United States is expecte...edicts. , That would bring the total by 2034 to...om 23.7 million today. , , At the same time, the..., the study also warns, rising from an estimated $...
(Date:11/27/2009)...gual coloring books designed for children ages 2 t...o educate - inform parents and children alike on a...rs to ABC,S and a host of other topics. , ...27, 2009 -- Today’s children have enough gad...ur of the day, but one of the oldest and simplest ...
(Date:11/26/2009)...ndfluseasonuponus,it,smoreimportantthanevertoemplo...idillness. ,, "Weneedtobeproactivenotonlytokeep...,resick,"saidEileenFinerty,RN,MS,CIC(certifiedinin...landoccupationalhealthatHospitalforSpecialSurgery(...soneofthelowestinfectionratesofanyhospitalinthecou...
Breaking Medicine News(10 mins):Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 2Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3Health News:Really Big Coloring Books Debuts Bi-Lingual Spanish-English Line of Custom and Imprintable Coloring Books 2Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 2Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 3
...swire/ -- WuXi PharmaTech (NYSE:,WX), a leading ph...earch,and development outsourcing company with ope...o announce that the distinguished Stanford Univers...: http://www.newscom.com/cgi-bin/prnh/20040705/CN...
... May 20 Accelerate Brain Cancer,Cure ( http://www...on its,website from leading brain cancer specialis...rain cancer study, as well as valuable guidance fo...ain cancer research and treatment,including:, Dr....
...linic researchers found that the frequency with wh...ssociated pneumonia (VAP) is approximately the sam...yo Clinic compared to the average VAP-risk rate fo...rong across the U.S. in intensive care units, whic...
...scious after swallowing Aqua Dots beads led to a v...t the time, it was widely reported that the potent...used in place of the benign but more expensive 1,5...eports, finding that Aqua Dots contained no 1,5-PD...
...wire/.- Speaker Nancy Pelosi,issued the following ...ennedy,s health:, "The news of Senator Kennedy,s ... Kennedy is a champion for health care for all Ame...e., "Our thoughts and prayers are with him, with ...
... draws specialists from across the ...al Werks, a leading provider of,ceramic components...ices,announced today that the Company will provide...,of disorders of the spine will convene at the Pal...
Other Medicine News:Health News:Stanford Professor Barry M. Trost Visits WuXi PharmaTech and Gives Two Seminars 2Health News:Brain Cancer Science and Treatment Information 2Health News:Intensive care units' prevention of pneumonia in critically-ill patients generally strong 2Health News:Study finds that recalled Aqua Dots did contain poisonous chemical 2Health News:C5 Medical Werks Joins in Sponsoring SpineWeek 2008 in Geneva, Switzerland 2
(Date:11/25/2009)...HAM,Mass.,Nov.25/PRNewswire/--AccordingtoMillenniu...hnologymarketintelligence,thenearly$3billionUSmark...owthoverthenextfiveyearsdespitetherecenteconomicsl...tfindsthatthismarketwillremainhighlydynamicoverthe...ddevicesinpreviouslyunderservedsegmentsofthetrauma...
(Date:11/25/2009)...T,TheNetherlandsandJOHANNESBURG,November25/PRNewsw...xisDiscoveryannouncedtoday,thattheyhavesignedacoll...rvices. , Pyxis,sworldclasscomputationalchemi...emba,sservicedivisiontoprovidemedicinaland,synthet...,internationalclientnetwork.iThembaPharmaceutical...
(Date:11/24/2009)...NE,Calif.,Nov.24/PRNewswire-FirstCall/--Endologix,...eatmentsforaorticdisorders,announcedtodaythatithas...hepatentinfringementlawsuitbroughtagainstitinOctob...sDistrictCourtinIndianapolis,Indiana. ,, Endolo...itedStatesPatentandTrademarkOffice(USPTO)conductsp...
Breaking Medicine Technology:US Trauma Fixation Device Market Not Seeing Signs of Slowdown 2US Trauma Fixation Device Market Not Seeing Signs of Slowdown 3iThemba Pharmaceuticals (Pty) Ltd and Pyxis Discovery B.V. Announce Collaborative Agreement to Offer a Combined Service Offering 2Endologix Files Motion to Discontinue Court Proceedings Related to Alleged Patent Infringement 2AMA Honors IL Ophthalmologist Manus C Kraff M D for Volunteer Eye Care for Military Members 60903 1AMA Honors IL Ophthalmologist Manus C Kraff M D for Volunteer Eye Care for Military Members 60903 2AMA Honors Medical Society Executives 60901 1AMA Honors Medical Society Executives 60901 2AMA Has Chance to Rescind Support of HR 3962 3B AMA Shout Out from Public Urges Doctors to Answer to PATIENTS Not AMA Leadership 60899 1
...--(BUSINESS WIRE)--May 2, 2007 - Acorda Therapeuti...om a Phase 3 clinical trial,of Fampridine-SR in pe...Academy of Neurology meeting. Andrew Goodman, M.D.... University of,Rochester, presented top-line resul...d clinician and subject global impressions.,Dr. Go...
...OD CITY, Calif., May 02, 2007 /PRNewswire-FirstCal...that a presentation was,made today at the 20th Int...held in Palm Springs, California, on a,non-nucleos...iscovered by Genelabs. , The oral presentation was...of Medicinal Chemistry at Genelabs, entitled,"GL59...
Other Medicine Technology:Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 2Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 3Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 4Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 5Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 6Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 7Genelabs Technologies Announces Presentation of Data on,Non-Nucleoside HCV Polymerase Inhibitor at 20th International,Conference on Antiviral Research Meeting 2Genelabs Technologies Announces Presentation of Data on,Non-Nucleoside HCV Polymerase Inhibitor at 20th International,Conference on Antiviral Research Meeting 3
Access Vitamin B12
...ked immunosorbent assay (ELISA) for the semi-quant... in human serum. The presence of ANA can be used i...oratory tests to aid in the diagnosis of rheumatic...gren's syndrome, scleroderma, and mixed connective...
...s that are compatible with multichannel pipettors,...ber of pipetting steps required to prepare and pla... Immuno Concepts for more information about this p... noted with an * after the catalog number and are ...
... to screen out patients negative for antinuclear a...mic rheumatic diseases such as Systemic lupus eryt...tive tissue disease, progressive systemic sclerosi... Raynaud's phenomenon. They can also be used in co...
Medicine Products: